Tirzepatide for Appetide and Weight Management
A New Frontier in Metabolic Research
$100.00
* This product is strictly for laboratory research use only and must not be used for human consumption, medical treatments, or any other non-research purposes.
What is Tirzepatide?
Tirzepatide is a dual GLP-1/GIP receptor agonist known for its appetite-suppressing and blood sugar-regulating effects. Originally developed for diabetes, it has gained significant attention in weight management research due to its ability to promote satiety and reduce body weight.
Mechanism of Action:
Tirzepatide activates both the GLP-1 and GIP receptors, which are involved in insulin secretion and blood sugar regulation. This dual action helps improve glucose tolerance and insulin sensitivity while reducing hunger.
Potential Benefits:
Weight Loss: Aids in reducing body fat by promoting satiety.
Appetite Suppression: Helps curb cravings and manage portions.
Improved Insulin Sensitivity: Supports glucose regulation, ideal for metabolic studies.
Cardiovascular Health: Potential to reduce cardiovascular risks associated with obesity.
Current Research Areas:
Obesity and Weight Management: Focused on fat reduction and appetite control.
Diabetes and Insulin Sensitivity: Studied for its effects on blood glucose and metabolic health.
Cardiovascular Health: Researching potential to reduce heart disease risks in obese individuals.
Dosage and Administration:
Common Research Dosage: 2.5-10 mg weekly, administered subcutaneously.
Timing: Taken once per week due to long half-life.
Additional Research References:
PubMed: Studies on Tirzepatide’s effects in metabolic health (PubMed).